CRISM Therapeutics Corporation (AIM:CRTX)

Market Cap	5.82M +174.0%
Revenue (ttm)	25.00K -44.4%
Net Income	-1.52M
EPS	-0.03
Shares Out	51.74M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	411,261
Average Volume	329,360
Open	11.25
Previous Close	11.25
Day's Range	11.25 - 12.00
52-Week Range	6.06 - 29.40
Beta	0.48
RSI	34.46
Earnings Date	May 27, 2026

About CRISM Therapeutics

CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs. Its lead product is ChemoSeed, an implantable biodegradable drug delivery technology for the delivery of chemotherapy directly into cancer tissues. The company also offers formulation and consultancy services. The company was formerly known as Amur Minerals Corporation and changed its name to CRISM Therapeutics Corporation in May 2024. CRISM Therapeutics Corporati...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 4
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CRTX

Financial Performance

In 2024, CRISM Therapeutics's revenue was 25,000, a decrease of -44.44% compared to the previous year's 45,000. Losses were -607,000, 209.7% more than in 2023.